Supported by unrestricted educational grants from Astellas Pharma Global Development, Inc. and Jazz Pharmaceuticals.
A Deeper Dive into Advanced and Future Directions in Treating Patients with Acute Myeloid Leukemia
Sandra E. Kurtin, PhDc, ANP-C, AOCN®
The University of Arizona Cancer Center
Gabrielle Zecha, PA-C
The University of Washington
Hear from expert advanced practitioners about the updated WHO classification criteria and today’s leading-edge treatments for AML. Also learn about the molecular mutations commonly associated with this disease and how to identify patients who are genetically predisposed.
These CME/CE/CPE accredited activities are jointly provided by